Trial Profile

A Phase 1, Multicenter, Randomized, Double-blind, Placebo- Controlled, Parallel Group Study to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Dec 2024 According to Red Queen Therapeutics media release, based on results from this study company has been working with the U.S. Food and Drug Administration (FDA) on a clinical development/registration plan for RQ-01 focused on treatment in combination with standard-of-care therapy, including antivirals, in high-risk immunocompromised patients.
06 Aug 2024 Results presented in the Apple Tree Partners Media Release.
16 Jun 2024 According to an Apple Tree Partners media release, the results from this trial were presented at the American Society for Microbiology (ASM) Microbe annual meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com